Sunrest Lifescie

how big is Sunrest Lifescie?

As of Jun 05, Sunrest Lifescience Ltd has a market capitalization of 21.00 Cr, with recent quarterly net sales of 5.64 Cr and a net profit of 0.75 Cr. The latest balance sheet shows shareholder's funds of 14.19 Cr and total assets of 25.13 Cr.

Market Cap: As of Jun 05, Sunrest Lifescience Ltd has a market capitalization of 21.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest quarter ending in June 2023, Sunrest Lifescience Ltd reported Net Sales of 5.64 Cr and a Net Profit of 0.75 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: The Standalone balance sheet for the latest annual period ending in March 2024 shows Shareholder's Funds of 14.19 Cr and Total Assets of 25.13 Cr.

What does Sunrest Lifescie do?

Sunrest Lifescience Ltd is a micro-cap healthcare services company that reported net sales of 6 Cr and a net profit of 1 Cr for June 2023. It has a market cap of Rs 21 Cr, a P/E ratio of 11.00, and a return on equity of 14.10%.

Overview: <BR>Sunrest Lifescience Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Sunrest Lifescience Ltd was originally incorporated as "Sunrest Lifescience Private Limited" in 2017. It later converted to a Public Limited Company and changed its name to "Sunrest Lifescience Limited." The most recent quarterly results reported net sales and net profit for June 2023.<BR><BR>Financial Snapshot: <BR>Net Sales: 6 Cr (Quarterly Results - Jun 2023) <BR>Net Profit: 1 Cr (Quarterly Results - Jun 2023) <BR>Market Cap: Rs 21 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 11.00 <BR>Industry P/E: 30 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.41 <BR>Return on Equity: 14.10% <BR>Price to Book: 1.51 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

Who are in the management team of Sunrest Lifescie?

As of March 2022, the management team of Sunrest Lifescie includes Juhi Sawajani (Chairperson), Nikhilkumar Y Thakkar (Managing Director), Amitbhai Shambhulal Thakkar (Whole-time Director), Bharatkumar V Thakkar (Executive Director), Bhagyesh Kiritbhai Parekh (Non-Executive Director), Avani Shah (Independent Director), and Nishi B Shah (Company Secretary & Compliance Officer). This team features a blend of executive and non-executive roles for effective governance and management.

As of March 2022, the management team of Sunrest Lifescie includes the following individuals:<BR><BR>1. Juhi Sawajani - Chairperson<BR>2. Nikhilkumar Y Thakkar - Managing Director<BR>3. Amitbhai Shambhulal Thakkar - Whole-time Director<BR>4. Bharatkumar V Thakkar - Executive Director<BR>5. Bhagyesh Kiritbhai Parekh - Non Executive Director<BR>6. Avani Shah - Independent Director<BR>7. Nishi B Shah - Company Secretary & Compliance Officer<BR><BR>This team comprises a mix of executive and non-executive roles, contributing to the governance and operational management of the company.

When is the next results date for Sunrest Lifescie?

No Upcoming Board Meetings

Has Sunrest Lifescie declared dividend?

No Dividend History Available

Who are the peers of the Sunrest Lifescie?

Sunrest Lifescie's peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Gian Lifecare, Vanta Bioscience, Clinitech Lab, Dhanvantri Jeev., and Ashram Online. Poly Medicure has the highest 1-year return at 24.45%, while Sunrest Lifescie's return is 0.00%.

Peers: The peers of Sunrest Lifescie are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Gian Lifecare, Vanta Bioscience, Clinitech Lab, Dhanvantri Jeev., and Ashram Online.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and Clinitech Lab. Below Average management risk is noted for Gian Lifecare and Dhanvantri Jeev., and Vanta Bioscience and Ashram Online do not qualify. Growth is Excellent at Sunrest Lifescie, while Below Average growth is seen at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., and Gian Lifecare. Average growth is found at Poly Medicure, Indegene, and the rest. Capital Structure is Excellent for Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and the rest, while Good capital structure is noted for Gian Lifecare and Clinitech Lab, and Dhanvantri Jeev. has a Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.45%, while Gian Lifecare has the lowest at -28.14%. Sunrest Lifescie's 1-year return is 0.00%, which is lower than both of these peers. Additionally, the six-month returns for Syngene Intl., Poly Medicure, Vijaya Diagnost., Gian Lifecare, Vanta Bioscience, Clinitech Lab, Dhanvantri Jeev., and Ashram Online are all negative.

What is the technical trend for Sunrest Lifescie?

As of May 16, 2025, Sunrest Lifescie has shifted to a bearish trend, supported by a bearish MACD, moving averages, and Bollinger Bands, indicating moderate strength in the bearish stance.

As of 16 May 2025, the technical trend for Sunrest Lifescie has changed from mildly bearish to bearish. The weekly MACD is bearish, and the daily moving averages confirm a bearish stance. The Bollinger Bands on the weekly chart also indicate a bearish trend, while the KST is bearish as well. The OBV shows a mildly bearish trend on both the weekly and monthly time frames. Overall, the current technical stance is bearish with moderate strength, driven primarily by the bearish MACD and moving averages.

Who are the top shareholders of the Sunrest Lifescie?

The top shareholder of Sunrest Lifescie is Nikhilkumar Yashvntlal Thakkar, with a 17.48% stake, while the highest public shareholder is Shardaben Dalsukhram Thakkar at 1.49%. Individual investors collectively own 24.94% of the shares, and there are no pledged promoter holdings or mutual funds/foreign institutional investors involved.

The top shareholders of Sunrest Lifescie include the promoters, with Nikhilkumar Yashvntlal Thakkar holding the highest stake at 17.48%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Shardaben Dalsukhram Thakkar, who holds 1.49%. Additionally, individual investors collectively hold 24.94% of the company's shares.

How has been the historical performance of Sunrest Lifescie?

Sunrest Lifescie reported a consolidated net profit of 2.01 crore for the year ending March 2025, with net sales and total operating income both at 33.41 crore. The company showed growth in profitability, a strengthened balance sheet, and positive cash flow from operating activities of 1.00 crore.

Answer:<BR>The historical performance of Sunrest Lifescie shows a consolidated net profit of 2.01 crore for the year ending March 2025, with net sales amounting to 33.41 crore. The total operating income for the same period was also 33.41 crore, while total expenditure, excluding depreciation, was 30.39 crore, resulting in an operating profit (PBDIT) of 3.02 crore. The profit before tax stood at 2.62 crore, leading to a profit after tax of 2.01 crore after accounting for tax expenses of 0.61 crore. The earnings per share (EPS) were reported at 4.69, with a PAT margin of 6.02%. <BR><BR>In terms of balance sheet metrics, the total assets of Sunrest Lifescie reached 35.13 crore, with total liabilities also at 35.13 crore, indicating a balanced position. The company’s shareholder's funds increased to 16.19 crore, up from 14.19 crore in the previous year. Long-term borrowings rose to 4.08 crore, while total debt remained stable at 6.16 crore. The book value per share adjusted to 37.72, reflecting a significant increase from previous years. Cash flow from operating activities showed a positive trend with 1.00 crore for the year, contrasting with a negative cash flow in the prior year. Overall, Sunrest Lifescie's financial performance indicates growth in sales and profitability, alongside a strengthening balance sheet.<BR><BR>Breakdown:<BR>Sunrest Lifescie's financial performance for the year ending March 2025 reveals a consolidated net profit of 2.01 crore, supported by net sales and total operating income both at 33.41 crore. The company incurred total expenditure of 30.39 crore, leading to an operating profit of 3.02 crore. After accounting for interest and tax, the profit before tax was 2.62 crore, resulting in a profit after tax of 2.01 crore. The earnings per share were reported at 4.69, with a PAT margin of 6.02%. On the balance sheet, total assets and total liabilities both stood at 35.13 crore, while shareholder's funds increased to 16.19 crore. Long-term borrowings rose to 4.08 crore, and total debt remained at 6.16 crore. The book value per share adjusted to 37.72, indicating growth. Cash flow from operating activities was positive at 1.00 crore, contrasting with the previous year's negative cash flow, highlighting a recovery in operational efficiency.

Is Sunrest Lifescie overvalued or undervalued?

As of November 27, 2025, Sunrest Lifescie has shifted from a fair to an attractive valuation grade, indicating it is undervalued with a PE ratio of 9.37 and strong growth potential compared to peers, despite a year-to-date return of -15.24% against the Sensex's 10.87%.

As of 27 November 2025, the valuation grade for Sunrest Lifescie has moved from fair to attractive, indicating a positive shift in its valuation outlook. The company appears to be undervalued, supported by a PE ratio of 9.37, an EV to EBITDA of 8.21, and a PEG ratio of 0.01, which suggests significant growth potential relative to its price. <BR><BR>In comparison to its peers, Sunrest Lifescie stands out with a more favorable PE ratio than Elitecon International, which is very expensive at 207.04, and MMTC, which is risky at 129.91. Additionally, PTC India, classified as very attractive, has a lower PE of 7.33, further highlighting Sunrest's competitive positioning in the market. Despite recent underperformance against the Sensex, with a year-to-date return of -15.24% compared to the Sensex's 10.87%, the company's strong fundamentals suggest it may present a compelling investment opportunity.

Why is Sunrest Lifescience Ltd falling/rising?

As of 04-Mar, Sunrest Lifescience Ltd's stock price is at 44.00, down 2.22%. This decline is due to recent negative performance, mixed moving average signals, and a significant drop in investor participation.

As of 04-Mar, Sunrest Lifescience Ltd's stock price is currently at 44.00, reflecting a decrease of 1.0, or 2.22%. This decline can be attributed to a combination of factors. <BR><BR>Firstly, the stock has experienced a negative performance over the past week, with a decrease of 2.22%, although it has outperformed the benchmark Sensex, which fell by 3.93% during the same period. However, the stock's performance over the last month shows a significant increase of 25.71%, indicating a recent upward trend that may not be sustaining. <BR><BR>Moreover, the stock's moving averages indicate mixed signals; it is higher than the 20-day, 50-day, and 100-day moving averages, but lower than the 5-day and 200-day moving averages. This suggests that while there was recent strength, the stock may be facing resistance at higher levels.<BR><BR>Additionally, there has been a notable decline in investor participation, with delivery volume dropping by 90.2% against the 5-day average, which could indicate waning interest from investors. Despite being liquid enough for trading, this drop in participation may contribute to the downward pressure on the stock price.<BR><BR>Overall, the combination of recent price declines, mixed moving average signals, and falling investor participation are key factors contributing to the current decrease in Sunrest Lifescience Ltd's stock price.

Which are the latest news on Sunrest Lifescie?